Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Authors' reply.

Wahba M, Sousa S, Watson S, Strawbridge R, Young AH, Lingford-Hughes A.

Br J Psychiatry. 2019 Sep;215(3):568-569. doi: 10.1192/bjp.2019.171. No abstract available.

PMID:
31397248
2.

Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2).

Lennox B, Yeeles K, Jones PB, Zandi M, Joyce E, Yu LM, Tomei G, Pollard R, Vincent SA, Shimazaki M, Cairns I, Dowling F, Kabir T, Barnes TRE, Lingford Hughes A, Hosseini AA, Harrower T, Buckley C, Coles A.

Trials. 2019 Jun 7;20(1):331. doi: 10.1186/s13063-019-3336-1.

3.
4.

A feasibility study of an intervention for structured preparation before detoxification in alcohol dependence: the SPADe trial protocol.

Kouimtsidis C, Houghton B, Gage H, Notley C, Maskrey V, Clark A, Holland R, Lingford-Hughes A, Punukollu B, Duka T.

Pilot Feasibility Stud. 2019 Apr 27;5:59. doi: 10.1186/s40814-019-0446-1. eCollection 2019.

5.

Alcohol Hangover: Underlying Biochemical, Inflammatory and Neurochemical Mechanisms.

Palmer E, Tyacke R, Sastre M, Lingford-Hughes A, Nutt D, Ward RJ.

Alcohol Alcohol. 2019 May 1;54(3):196-203. doi: 10.1093/alcalc/agz016.

PMID:
30916313
6.

The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective.

de Beaurepaire R, Sinclair JMA, Heydtmann M, Addolorato G, Aubin HJ, Beraha EM, Caputo F, Chick JD, de La Selle P, Franchitto N, Garbutt JC, Haber PS, Jaury P, Lingford-Hughes AR, Morley KC, Müller CA, Owens L, Pastor A, Paterson LM, Pélissier F, Rolland B, Stafford A, Thompson A, van den Brink W, Leggio L, Agabio R.

Front Psychiatry. 2019 Jan 4;9:708. doi: 10.3389/fpsyt.2018.00708. eCollection 2018. Review.

7.

Using Baclofen to Explore GABA-B Receptor Function in Alcohol Dependence: Insights From Pharmacokinetic and Pharmacodynamic Measures.

Durant CF, Paterson LM, Turton S, Wilson SJ, Myers JFM, Muthukumaraswamy S, Venkataraman A, Mick I, Paterson S, Jones T, Nahar LK, Cordero RE, Nutt DJ, Lingford-Hughes A.

Front Psychiatry. 2018 Dec 14;9:664. doi: 10.3389/fpsyt.2018.00664. eCollection 2018.

8.

Unleashing talent in mental health sciences: gender equality at the top.

Breedvelt JJF, Rowe S, Bowden-Jones H, Shridhar S, Lovett K, Bockting C, Lingford-Hughes A, Strathdee G, Tracy DK.

Br J Psychiatry. 2018 Dec;213(6):679-681. doi: 10.1192/bjp.2018.249.

9.

Baclofen for the treatment of alcohol use disorder: the Cagliari Statement.

Agabio R, Sinclair JM, Addolorato G, Aubin HJ, Beraha EM, Caputo F, Chick JD, de La Selle P, Franchitto N, Garbutt JC, Haber PS, Heydtmann M, Jaury P, Lingford-Hughes AR, Morley KC, Müller CA, Owens L, Pastor A, Paterson LM, Pélissier F, Rolland B, Stafford A, Thompson A, van den Brink W, de Beaurepaire R, Leggio L.

Lancet Psychiatry. 2018 Dec;5(12):957-960. doi: 10.1016/S2215-0366(18)30303-1. Epub 2018 Nov 6. No abstract available.

10.

Naltrexone differentially modulates the neural correlates of motor impulse control in abstinent alcohol-dependent and polysubstance-dependent individuals.

Nestor LJ, Paterson LM, Murphy A, McGonigle J, Orban C, Reed L, Taylor E, Flechais R, Smith D, Bullmore ET, Ersche KD, Suckling J, Elliott R, Deakin B, Rabiner I, Lingford Hughes A, Sahakian BJ, Robbins TW, Nutt DJ; ICCAM Consortium.

Eur J Neurosci. 2019 Aug;50(3):2311-2321. doi: 10.1111/ejn.14262. Epub 2018 Nov 26.

PMID:
30402987
11.

GABAA receptor availability is not altered in adults with autism spectrum disorder or in mouse models.

Horder J, Andersson M, Mendez MA, Singh N, Tangen Ä, Lundberg J, Gee A, Halldin C, Veronese M, Bölte S, Farde L, Sementa T, Cash D, Higgins K, Spain D, Turkheimer F, Mick I, Selvaraj S, Nutt DJ, Lingford-Hughes A, Howes OD, Murphy DG, Borg J.

Sci Transl Med. 2018 Oct 3;10(461). pii: eaam8434. doi: 10.1126/scitranslmed.aam8434.

12.

A transdiagnostic dimensional approach towards a neuropsychological assessment for addiction: an international Delphi consensus study.

Yücel M, Oldenhof E, Ahmed SH, Belin D, Billieux J, Bowden-Jones H, Carter A, Chamberlain SR, Clark L, Connor J, Daglish M, Dom G, Dannon P, Duka T, Fernandez-Serrano MJ, Field M, Franken I, Goldstein RZ, Gonzalez R, Goudriaan AE, Grant JE, Gullo MJ, Hester R, Hodgins DC, Le Foll B, Lee RSC, Lingford-Hughes A, Lorenzetti V, Moeller SJ, Munafò MR, Odlaug B, Potenza MN, Segrave R, Sjoerds Z, Solowij N, van den Brink W, van Holst RJ, Voon V, Wiers R, Fontenelle LF, Verdejo-Garcia A.

Addiction. 2019 Jun;114(6):1095-1109. doi: 10.1111/add.14424. Epub 2018 Oct 5.

13.

Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals.

Turton S, Myers JF, Mick I, Colasanti A, Venkataraman A, Durant C, Waldman A, Brailsford A, Parkin MC, Dawe G, Rabiner EA, Gunn RN, Lightman SL, Nutt DJ, Lingford-Hughes A.

Mol Psychiatry. 2018 Jun 25. doi: 10.1038/s41380-018-0107-4. [Epub ahead of print]

14.

Joint BAP NAPICU evidence-based consensus guidelines for the clinical management of acute disturbance: De-escalation and rapid tranquillisation.

Patel MX, Sethi FN, Barnes TR, Dix R, Dratcu L, Fox B, Garriga M, Haste JC, Kahl KG, Lingford-Hughes A, McAllister-Williams H, O'Brien A, Parker C, Paterson B, Paton C, Posporelis S, Taylor DM, Vieta E, Völlm B, Wilson-Jones C, Woods L; With co-authors (in alphabetical order):.

J Psychopharmacol. 2018 Jun;32(6):601-640. doi: 10.1177/0269881118776738. Epub 2018 Jun 8.

PMID:
29882463
15.

Cerebral blood flow predicts differential neurotransmitter activity.

Dukart J, Holiga Š, Chatham C, Hawkins P, Forsyth A, McMillan R, Myers J, Lingford-Hughes AR, Nutt DJ, Merlo-Pich E, Risterucci C, Boak L, Umbricht D, Schobel S, Liu T, Mehta MA, Zelaya FO, Williams SC, Brown G, Paulus M, Honey GD, Muthukumaraswamy S, Hipp J, Bertolino A, Sambataro F.

Sci Rep. 2018 Mar 6;8(1):4074. doi: 10.1038/s41598-018-22444-0.

16.

Minocycline reduces chronic microglial activation after brain trauma but increases neurodegeneration.

Scott G, Zetterberg H, Jolly A, Cole JH, De Simoni S, Jenkins PO, Feeney C, Owen DR, Lingford-Hughes A, Howes O, Patel MC, Goldstone AP, Gunn RN, Blennow K, Matthews PM, Sharp DJ.

Brain. 2018 Feb 1;141(2):459-471. doi: 10.1093/brain/awx339.

17.

Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.

Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, Robbins TW, Lingford-Hughes A, Nutt DJ, Deakin JFW, Elliott R; ICCAM Platform.

Neuropsychopharmacology. 2017 Aug;42(9):1925-1926. doi: 10.1038/npp.2017.99.

18.

Challenges the addiction field must overcome to avert being the Cinderella of medicine.

Lingford-Hughes A.

Addiction. 2017 Dec;112(12):2095-2096. doi: 10.1111/add.13894. Epub 2017 Jul 6. No abstract available.

PMID:
28685900
19.

Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.

Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, Robbins TW, Lingford-Hughes A, Nutt DJ, Deakin JF, Elliott R; ICCAM Platform.

Neuropsychopharmacology. 2017 Jun;42(7):1559. doi: 10.1038/npp.2017.47. No abstract available.

20.

British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017.

McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, Green L, Gregoire A, Howard LM, Jones I, Khalifeh H, Lingford-Hughes A, McDonald E, Micali N, Pariante CM, Peters L, Roberts A, Smith NC, Taylor D, Wieck A, Yates LM, Young AH; endorsed by the British Association for Psychopharmacology.

J Psychopharmacol. 2017 May;31(5):519-552. doi: 10.1177/0269881117699361. Epub 2017 Apr 25.

21.

Reframing the science and policy of nicotine, illegal drugs and alcohol - conclusions of the ALICE RAP Project.

Anderson P, Berridge V, Conrod P, Dudley R, Hellman M, Lachenmeier D, Lingford-Hughes A, Miller D, Rehm J, Room R, Schmidt L, Sullivan R, Ysa T, Gual A.

F1000Res. 2017 Mar 17;6:289. doi: 10.12688/f1000research.10860.1. eCollection 2017.

22.

Interdisciplinary working in public health research: a proposed good practice checklist.

Gavens L, Holmes J, Bühringer G, McLeod J, Neumann M, Lingford-Hughes A, Hock ES, Meier PS.

J Public Health (Oxf). 2018 Mar 1;40(1):175-182. doi: 10.1093/pubmed/fdx027.

23.

11C-PBR28 and 18F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis.

Datta G, Colasanti A, Kalk N, Owen D, Scott G, Rabiner EA, Gunn RN, Lingford-Hughes A, Malik O, Ciccarelli O, Nicholas R, Nei L, Battaglini M, Stefano ND, Matthews PM.

J Nucl Med. 2017 Sep;58(9):1477-1482. doi: 10.2967/jnumed.116.187161. Epub 2017 Mar 16.

24.

Effects of naltrexone are influenced by childhood adversity during negative emotional processing in addiction recovery.

Savulich G, Riccelli R, Passamonti L, Correia M, Deakin JF, Elliott R, Flechais RS, Lingford-Hughes AR, McGonigle J, Murphy A, Nutt DJ, Orban C, Paterson LM, Reed LJ, Smith DG, Suckling J, Tait R, Taylor EM, Sahakian BJ, Robbins TW, Ersche KD.

Transl Psychiatry. 2017 Mar 7;7(3):e1054. doi: 10.1038/tp.2017.34.

25.

Naltrexone ameliorates functional network abnormalities in alcohol-dependent individuals.

Morris LS, Baek K, Tait R, Elliott R, Ersche KD, Flechais R, McGonigle J, Murphy A, Nestor LJ, Orban C, Passetti F, Paterson LM, Rabiner I, Reed L, Smith D, Suckling J, Taylor EM, Bullmore ET, Lingford-Hughes AR, Deakin B, Nutt DJ, Sahakian BJ, Robbins TW, Voon V; ICCAM Consortium.

Addict Biol. 2018 Jan;23(1):425-436. doi: 10.1111/adb.12503. Epub 2017 Feb 28.

26.

Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study.

Quelch DR, Mick I, McGonigle J, Ramos AC, Flechais RSA, Bolstridge M, Rabiner E, Wall MB, Newbould RD, Steiniger-Brach B, van den Berg F, Boyce M, Østergaard Nilausen D, Breuning Sluth L, Meulien D, von der Goltz C, Nutt D, Lingford-Hughes A.

Biol Psychiatry. 2017 Jun 1;81(11):941-948. doi: 10.1016/j.biopsych.2016.12.029. Epub 2017 Jan 10.

27.

Alcohol and Alzheimer's Disease-Does Alcohol Dependence Contribute to Beta-Amyloid Deposition, Neuroinflammation and Neurodegeneration in Alzheimer's Disease?

Venkataraman A, Kalk N, Sewell G, W Ritchie C, Lingford-Hughes A.

Alcohol Alcohol. 2017 Mar 9;52(2):158. doi: 10.1093/alcalc/agw101. Review. No abstract available.

28.

Introduction to Horizons Review series on neuroimaging.

Lingford-Hughes A.

Addiction. 2017 Feb;112(2):205-206. doi: 10.1111/add.13694. No abstract available.

PMID:
28078700
29.

Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [11C]PBR28 PET study.

Kalk NJ, Guo Q, Owen D, Cherian R, Erritzoe D, Gilmour A, Ribeiro AS, McGonigle J, Waldman A, Matthews P, Cavanagh J, McInnes I, Dar K, Gunn R, Rabiner EA, Lingford-Hughes AR.

Transl Psychiatry. 2017 Jan 10;7(1):e996. doi: 10.1038/tp.2016.264.

30.

Neural substrates of cue reactivity and craving in gambling disorder.

Limbrick-Oldfield EH, Mick I, Cocks RE, McGonigle J, Sharman SP, Goldstone AP, Stokes PR, Waldman A, Erritzoe D, Bowden-Jones H, Nutt D, Lingford-Hughes A, Clark L.

Transl Psychiatry. 2017 Jan 3;7(1):e992. doi: 10.1038/tp.2016.256.

31.

Acute D3 Antagonist GSK598809 Selectively Enhances Neural Response During Monetary Reward Anticipation in Drug and Alcohol Dependence.

Murphy A, Nestor LJ, McGonigle J, Paterson L, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, Metastasio A, Orban C, Passetti F, Reed L, Smith D, Suckling J, Taylor E, Robbins TW, Lingford-Hughes A, Nutt DJ, Deakin JF, Elliott R.

Neuropsychopharmacology. 2017 Apr;42(5):1049-1057. doi: 10.1038/npp.2016.289. Epub 2017 Jan 2. Erratum in: Neuropsychopharmacology. 2017 Jun;42(7):1559. Neuropsychopharmacology. 2017 Aug;42(9):1925-1926.

32.

Alcohol and Alzheimer's Disease-Does Alcohol Dependence Contribute to Beta-Amyloid Deposition, Neuroinflammation and Neurodegeneration in Alzheimer's Disease?

Venkataraman A, Kalk N, Sewell G, Ritchie CW, Lingford-Hughes A.

Alcohol Alcohol. 2017 Mar 9;52(2):151-158. doi: 10.1093/alcalc/agw092. Review. Erratum in: Alcohol Alcohol. 2017 Mar 9;52(2):158.

33.

Evidence for GABA-A receptor dysregulation in gambling disorder: correlation with impulsivity.

Mick I, Ramos AC, Myers J, Stokes PR, Chandrasekera S, Erritzoe D, Mendez MA, Gunn RN, Rabiner EA, Searle GE, Galduróz JCF, Waldman AD, Bowden-Jones H, Clark L, Nutt DJ, Lingford-Hughes AR.

Addict Biol. 2017 Nov;22(6):1601-1609. doi: 10.1111/adb.12457. Epub 2016 Oct 13.

34.

The ICCAM platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part B: fMRI description.

McGonigle J, Murphy A, Paterson LM, Reed LJ, Nestor L, Nash J, Elliott R, Ersche KD, Flechais RS, Newbould R, Orban C, Smith DG, Taylor EM, Waldman AD, Robbins TW, Deakin JW, Nutt DJ, Lingford-Hughes AR, Suckling J; ICCAM Platform.

J Psychopharmacol. 2017 Jan;31(1):3-16. doi: 10.1177/0269881116668592. Epub 2016 Oct 4.

35.

Improving GHB withdrawal with baclofen: study protocol for a feasibility study for a randomised controlled trial.

Lingford-Hughes A, Patel Y, Bowden-Jones O, Crawford MJ, Dargan PI, Gordon F, Parrott S, Weaver T, Wood DM.

Trials. 2016 Sep 27;17(1):472.

36.

Acute naltrexone does not remediate fronto-striatal disturbances in alcoholic and alcoholic polysubstance-dependent populations during a monetary incentive delay task.

Nestor LJ, Murphy A, McGonigle J, Orban C, Reed L, Taylor E, Flechais R, Paterson LM, Smith D, Bullmore ET, Ersche KD, Suckling J, Tait R, Elliott R, Deakin B, Rabiner I, Lingford-Hughes A, Nutt DJ, Sahakian B, Robbins TW; ICCAM Consortium.

Addict Biol. 2017 Nov;22(6):1576-1589. doi: 10.1111/adb.12444. Epub 2016 Sep 6.

37.

Comparison of cannabinoids in hair with self-reported cannabis consumption in heavy, light and non-cannabis users.

Taylor M, Lees R, Henderson G, Lingford-Hughes A, Macleod J, Sullivan J, Hickman M.

Drug Alcohol Rev. 2017 Mar;36(2):220-226. doi: 10.1111/dar.12412. Epub 2016 Jun 14.

38.

Significant reductions in human visual gamma frequency by the gaba reuptake inhibitor tiagabine revealed by robust peak frequency estimation.

Magazzini L, Muthukumaraswamy SD, Campbell AE, Hamandi K, Lingford-Hughes A, Myers JF, Nutt DJ, Sumner P, Wilson SJ, Singh KD.

Hum Brain Mapp. 2016 Nov;37(11):3882-3896. doi: 10.1002/hbm.23283.

39.

BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment.

Cooper SJ, Reynolds GP; With expert co-authors (in alphabetical order):, Barnes T, England E, Haddad PM, Heald A, Holt R, Lingford-Hughes A, Osborn D, McGowan O, Patel MX, Paton C, Reid P, Shiers D, Smith J.

J Psychopharmacol. 2016 Aug;30(8):717-48. doi: 10.1177/0269881116645254. Epub 2016 May 4.

PMID:
27147592
40.

γ-aminobutyric acid as a metabolite: Interpreting magnetic resonance spectroscopy experiments.

Myers JF, Nutt DJ, Lingford-Hughes AR.

J Psychopharmacol. 2016 May;30(5):422-7. doi: 10.1177/0269881116639298. Epub 2016 Mar 22. Review.

PMID:
27005308
41.

Substitution treatment in addiction: there is more than one way...

Lingford-Hughes A.

Addiction. 2016 May;111(5):776-7. doi: 10.1111/add.13288. Epub 2016 Feb 23. No abstract available.

42.

Impulsivity in abstinent alcohol and polydrug dependence: a multidimensional approach.

Taylor EM, Murphy A, Boyapati V, Ersche KD, Flechais R, Kuchibatla S, McGonigle J, Metastasio A, Nestor L, Orban C, Passetti F, Paterson L, Smith D, Suckling J, Tait R, Lingford-Hughes AR, Robbins TW, Nutt DJ, Deakin JF, Elliott R; ICCAM Platform.

Psychopharmacology (Berl). 2016 Apr;233(8):1487-99. doi: 10.1007/s00213-016-4245-6. Epub 2016 Feb 25.

43.

Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism.

Lingford-Hughes A, Myers J, Watson B, Reid AG, Kalk N, Feeney A, Hammers A, Riaño-Barros DA, McGinnity CJ, Taylor LG, Rosso L, Brooks DJ, Turkheimer F, Nutt DJ.

Neuroimage. 2016 May 15;132:1-7. doi: 10.1016/j.neuroimage.2016.02.005. Epub 2016 Feb 11.

44.

Antidepressant treatment response: 'I want it all, and I want it now!'†.

Malhi GS, Lingford-Hughes AR, Young AH.

Br J Psychiatry. 2016 Feb;208(2):101-3. doi: 10.1192/bjp.bp.115.176479.

PMID:
26834163
45.

Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers.

Mick I, Myers J, Ramos AC, Stokes PR, Erritzoe D, Colasanti A, Gunn RN, Rabiner EA, Searle GE, Waldman AD, Parkin MC, Brailsford AD, Galduróz JC, Bowden-Jones H, Clark L, Nutt DJ, Lingford-Hughes AR.

Neuropsychopharmacology. 2016 Jun;41(7):1742-50. doi: 10.1038/npp.2015.340. Epub 2015 Nov 10.

46.

Validated Method for the Quantification of Baclofen in Human Plasma Using Solid-Phase Extraction and Liquid Chromatography-Tandem Mass Spectrometry.

Nahar LK, Cordero RE, Nutt D, Lingford-Hughes A, Turton S, Durant C, Wilson S, Paterson S.

J Anal Toxicol. 2016 Mar;40(2):117-23. doi: 10.1093/jat/bkv125. Epub 2015 Nov 4.

47.

The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.

Paterson LM, Flechais RS, Murphy A, Reed LJ, Abbott S, Boyapati V, Elliott R, Erritzoe D, Ersche KD, Faluyi Y, Faravelli L, Fernandez-Egea E, Kalk NJ, Kuchibatla SS, McGonigle J, Metastasio A, Mick I, Nestor L, Orban C, Passetti F, Rabiner EA, Smith DG, Suckling J, Tait R, Taylor EM, Waldman AD, Robbins TW, Deakin JF, Nutt DJ, Lingford-Hughes AR; ICCAM Platform.

J Psychopharmacol. 2015 Sep;29(9):943-60. doi: 10.1177/0269881115596155. Epub 2015 Aug 5.

48.

Ethanol Reversal of Tolerance to the Respiratory Depressant Effects of Morphine.

Hill R, Lyndon A, Withey S, Roberts J, Kershaw Y, MacLachlan J, Lingford-Hughes A, Kelly E, Bailey C, Hickman M, Henderson G.

Neuropsychopharmacology. 2016 Feb;41(3):762-73. doi: 10.1038/npp.2015.201. Epub 2015 Jul 14.

49.

The dopamine theory of addiction: 40 years of highs and lows.

Nutt DJ, Lingford-Hughes A, Erritzoe D, Stokes PR.

Nat Rev Neurosci. 2015 May;16(5):305-12. doi: 10.1038/nrn3939. Epub 2015 Apr 15. Review.

PMID:
25873042
50.

Influence of agonist induced internalization on [3H]Ro15-4513 binding-an application to imaging fluctuations in endogenous GABA with positron emission tomography.

Quelch D, De Santis V, Strege A, Myers J, Wells L, Nutt D, Lingford-Hughes A, Parker C, Tyacke R.

Synapse. 2015 Jan;69(1):60-5. doi: 10.1002/syn.21780. Epub 2014 Sep 19.

PMID:
25196273

Supplemental Content

Loading ...
Support Center